Skip to main content

Table 9 Approved cannabis-based drugs by a national regulatory authority for clinical use and related patent data

From: Trends in intellectual property rights protection for medical cannabis and related products

Drug proprietary name Active pharmaceutical ingredient Medical condition Company Country and year of approval Relevant patents and dates of expiry
Cesamet Nabilone (synthetic cannabinoid) Nausea, Multiple sclerosis, Fibromyalgia Eli Lilly, Valeant USA, 1985,2006, UK, EU Austria, Belgium, Spain, variously from 2007 US4195078—expired 1999
EP2004075590—expired 2018
Epidiolex Cannabidiol (CBD) Epilepsy GW Pharma USA 2018
EU 2019
US10/468041—expiry date 2026
US9956185—expiry date 2035
US9066920—expiry date 2032
Marinol Dronabinol (synthetic Tetrahydrocannabinol (THC) HIV/AIDS-induced anorexia and chemotherapy-induced nausea and vomiting Solvay Pharmaceuticals USA 1985, 1992 US5166145—expired 2010
US6383513—expired 2018
Sativex THC and CBD in a 1:1 ratio neuropathic pain, spasticity, overactive bladder, and other symptoms of multiple sclerosis GW Pharma UK 2010 and various European countries, Canada 2005 US20060135599A1—expiry date 2022
US10538373—estimated expiry date 2022
Syndros Synthetic THC (Dronabinol) in liquid formulation for oral administration Nausea and vomiting caused by chemotherapy, loss of appetite Insys Therapeutics US 2016 US9345771—expiry date 2028
US8222292—expiry date 2028